Percutaneous repair by MitraClip is a transcatheter technology based on the surgical Alfieri edge-to-edge repair, which involves suturing together the middle segments of the anterior and posterior
mitral valve leaflets, thereby creating a "double orifice"
mitral regurgitant area.5 The MitraClip system utilizes a cobalt chromium clip covered with a polypropylene fabric that grasps the leaflet and reduces
mitral regurgitation (MR) by increasing the coaptation between the regurgitant valve leaflets.
The narrowing down of the
mitral valve obstructs the blood flow from the left atrium to the left ventricle of the heart.
According to the company, the MitraClip device repairs leaky
mitral valves without open-heart surgery and is delivered to the heart through a small incision in the leg.
"The technology enables us to see all angles of the
mitral valve perfectly in three dimensions," says Per Wierup, MD, one of three Cleveland Clinic heart surgeons with robotic expertise and experience.
that participated in the clinical trial that lead to the FDA approval of this device for patients with functional
mitral regurgitation.
One of the major causative agent leading to
mitral stenosis (MS) is Rheumatic fever (RF)1.
Cephea's technology is being developed to provide an option for people whose diseased
mitral valves need to be replaced.
Percepcoes sobre a valvula
mitral canina no curso da doenca
mitral mixomatosa
Os pacientes portadores desta condicao comumente sao assintomaticos, no entanto quando sintomaticos, poderao apresentar mais frequentemente dispneia, devido a estenose ou insuficiencia
mitral, alem de palpitacao e sincope e, apesar de serem incomuns, fenomenos embolicos tambem podem acontecer (FRANCA et al., 2013, p.371; BOHATCH JUNIOR et al., 2015, p.242; ASSUNCAO et al., 2016, p.274).
Severe
mitral regurgitation is associated with incremental mortality in patients with LV systolic dysfunction, (1,2) and this is evident both in patients with ischemic and non-ischemic cardiomyopathies.
We retrospectively analyzed 252 consecutive patients with degenerative
mitral valve disease who underwent
mitral repair in the Cardio-Thoracic Center of Monaco between January 2010 and December 2016.